• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $COYA

    Coya Therapeutics Inc.

    Subscribe to $COYA
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2022

    Exchange: NASDAQ

    Recent Analyst Ratings for Coya Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/4/2024$15.00Buy
    D. Boral Capital
    See more ratings

    Coya Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in two upcoming conferences in May 2025. Chief Executive Officer Arun Swaminathan, Ph.D. and Chief Financial Officer David Snyder will be available for one-on-one meetings with registered investors of the following conferences: Event: D. Boral Capital Inaugural Global Conference Date: May 14, 2025 Registration: Contact John Perez at [email protected] Location: The Plaza Hotel 768 Fifth Avenue New York, NY 10019   Event:

      5/8/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

      COYA 303 is an investigational biologic combination of COYA 301, Coya's low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells, compared to the individual components - LD IL-2 and GLP-1RA Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced publication o

      4/21/25 9:51:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

      Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated "Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer's disease" Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer's disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna. The presentation, titled, "A Phase II Clinical Trial o

      4/1/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

      Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study Funded by the Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer, with Coya holding exclusive rights

      3/26/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD) Announced that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combinat

      3/18/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast "Is Alzheimer's next for GLP-1s and Combos?" on February 27, 2025 to discuss the potential treatment of Alzheimer's disease using GLP-1 agonists and combination therapy. Juliette Lafille, Managing Director, Healthcare Sector Specialist at BTIG, will moderate the discussion. The topics of the discussion will include: Potential

      2/25/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

      Investigator-initiated data from Houston Methodist Hospital showed LD IL-2 reduced proinflammatory factors, both systemically and within the central nervous system, while demonstrating statistically significant improvement in beta amyloid 42 clearance with stabilization of cognitive decline over a five-month treatment period Comprehensive data set will be presented and released throughout 2025 and in a peer reviewed publication Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging blood biomarker data from an investigator-initiated, 21-week,

      2/6/25 8:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11-12, 2025 in a virtual format. Event:   Oppenheimer 35th Annual Healthcare Life Sciences Conference Presentation Date:   Tuesday, February 11, 2025 Presentation Time:   10:00 - 10:30 AM ET in Track 3 Webcast Link:   https://wsw.com/webcast/oppenheimer39/coya/2780384 An archived webcast of the

      2/4/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

      SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      11/12/24 3:37:54 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

      SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      11/4/24 1:27:32 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

      SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      11/4/24 11:42:58 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Coya Therapeutics Inc.

      10-K/A - Coya Therapeutics, Inc. (0001835022) (Filer)

      4/28/25 5:07:30 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Coya Therapeutics Inc.

      10-K - Coya Therapeutics, Inc. (0001835022) (Filer)

      3/18/25 8:26:15 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

      3/18/25 8:20:22 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Coya Therapeutics Inc.

      SCHEDULE 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      2/14/25 4:26:38 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Coya Therapeutics Inc.

      SCHEDULE 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

      2/10/25 8:35:18 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Coya Therapeutics Inc.

      S-8 - Coya Therapeutics, Inc. (0001835022) (Filer)

      1/30/25 5:01:14 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Coya Therapeutics Inc.

      EFFECT - Coya Therapeutics, Inc. (0001835022) (Filer)

      12/2/24 12:15:12 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Coya Therapeutics Inc.

      424B3 - Coya Therapeutics, Inc. (0001835022) (Filer)

      11/29/24 4:15:40 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Coya Therapeutics Inc.

      S-3 - Coya Therapeutics, Inc. (0001835022) (Filer)

      11/20/24 5:15:59 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Coya Therapeutics Inc.

      10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)

      11/6/24 8:06:38 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Snyder David S bought $12,934 worth of shares (1,800 units at $7.19), increasing direct ownership by 26% to 8,800 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/14/24 6:08:32 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Swaminathan Arun bought $36,797 worth of shares (5,000 units at $7.36), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/13/24 4:05:16 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Grossman Fred bought $19,973 worth of shares (2,710 units at $7.37) (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/12/24 6:03:34 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Swaminathan Arun bought $36,689 worth of shares (5,000 units at $7.34) (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/12/24 4:58:37 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lee Ann bought $3,620 worth of shares (1,000 units at $3.62) (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      3/5/24 8:00:30 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Coya Therapeutics with a new price target

      D. Boral Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $15.00

      12/4/24 7:30:44 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weinand Dieter

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:04 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ross Wilbur L Jr

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:03 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lee Ann

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:08 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Goldstein Dov A Md

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:05 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Villalobos Anabella

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      2/25/25 9:30:07 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Grossman Fred

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      1/13/25 8:00:05 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Swaminathan Arun

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      1/13/25 8:00:06 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Berman Howard

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      1/13/25 8:00:03 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Snyder David S

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      1/13/25 8:00:07 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Villalobos Anabella

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      1/3/25 9:30:20 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

      Secretary Ross has over 55 years' experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross's extensive experience in both the business and investment community to help guide strategic partnering activities, capital markets initiatives and drug development programs. S

      12/20/23 8:30:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, As the year comes to a close, I want to take a moment to reflect on Coya's accomplishments and share our strategic vision for the coming year. We set ambitious goals at the beginning of 2023 and I am pleased to say that our team rose to the occasion. Throughout the year, we notched several "wins," culminating in a transformative licensing transaction, announced December 6th, 2023, with Dr

      12/13/23 8:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Announces $26.5 Million Private Placement

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions. The financing included participation by former U.S. Secretary of Commerce Wi

      12/6/23 7:05:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya's Board of Directors

      Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer's fully integrated $20 billion healthcare business Mr. Weinand is a seasoned business leader with over 25 years of experience leading business and strategic operations for companies including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and Otsuka Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand's extens

      8/21/23 7:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Coya Therapeutics ("Coya") Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

      Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chief of Neurology at Mass General, Director and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Cudkowicz's research and clinical activities are dedicated to the study and treatment of people with ALS; she is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), a group of over 134 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative clinical trials and research in ALS. Dr. Cudkowicz will support the development of Coya's most advanced clinical asset, COYA 302, a dual-mechanism investigational biol

      7/19/23 7:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner

      Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc. (NASDAQ:MESO). Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association

      7/5/23 8:30:00 AM ET
      $COYA
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

      Dr. Frazier brings over 20 years of strong regulatory expertise since her tenure at the FDA followed by a successful career in the pharmaceutical industry. Dr. Frazier spent 7 years at the FDA, where she was a team lead reviewing over 60 new molecular entities, overseeing multiple biologic license applications, including the first anti-angiogenic monoclonal antibody approved for cancer therapy. In turn, she was recognized multiple times for her leadership and excellence. Subsequent to FDA, Dr. Frazier has demonstrated a proven track record for overseeing and guiding successful global regulatory strategies at prestigious bio pharmaceutical companies for numerous biologic drug products

      6/14/23 7:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, It's hard to believe it's now 6 months since our IPO closed on January 3rd of this year. We launched our IPO into one of the toughest biotech capital markets in recent memory and are enormously grateful to all our investors for the confidence they then showed in our prospects. I believe that to date, we've executed strongly against the goals we then established, and I remain excited about

      6/12/23 7:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Coya Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

      10/28/24 8:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As

      11/8/23 9:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a

      8/8/23 7:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET

      The proof-of-concept open-label study evaluated the safety and tolerability, function of regulatory T cells (Tregs), biomarkers, and preliminary efficacy (as measured by the ALSFRS-R scale) of COYA 302 over 48 weeks and was conducted in four ALS patients at the Houston Methodist Hospital by Dr. Stanley Appel and Dr. Jason Thonhoff. Study data showed no decline or minimal decline at 24 and 48 weeks, respectively, after initiation of treatment in a group of patients experiencing a mean decline of -1.1 points/month in their ALSFRS-R score prior to initiation of treatment with COYA 302. The mean (±SD) ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment

      3/21/23 7:50:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present clinical data of Coya's proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), on Tuesday, March 21, 2023 at 8:00am ET. During the call, Dr. Stanley Appel, the chair of Coya's Scientific Advisory Board, will provide commentary on the data summarizing work conducted at his lab at Houston Methodist Hospital. Following Dr. Appel's comment's, Dr. Howard Berman,

      3/9/23 7:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care